SB-19642

N/A

Report date: 2025/11/13 10:07:42
NME

Base Information

Drug NameSB-19642
Drug Alias NameSingle stranded, synthetic, hybrid RNA/DNA antisense oligonucleotide (ASO) gapmer targeting the TUBB4A geneSB-19642
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionTubulin beta-4A chain modulators
TargetsTubulin beta-4A chain
Therapy Area/IndicationsLeukoencephalopathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSynaptixBio Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSynaptixBio Ltd
Inactive CompaniesN/A
Active IndicationsLeukoencephalopathies
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A